# LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

> **NCT03412890** · PHASE3 · COMPLETED · sponsor: **Myovant Sciences GmbH** · enrollment: 477 (actual)

## Conditions studied

- Heavy Menstrual Bleeding
- Uterine Fibroid

## Interventions

- **DRUG:** Relugolix
- **DRUG:** Estradiol/norethindrone acetate

## Key facts

- **NCT ID:** NCT03412890
- **Lead sponsor:** Myovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-19
- **Primary completion:** 2020-01-21
- **Final completion:** 2021-01-13
- **Target enrollment:** 477 (ACTUAL)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412890, "LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03412890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*